NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company has submitted a supplemental New Drug Application (sNDA) for TRULANCE™ (plecanatide) for the ...

Synergy is set to launch Trulance this month and file an sNDA for IBS-C. Trulance competitor Linzess may be causing significant weight gain in some patients. The trulance launch looks very similar to ...

New bowel drug Trulance will be available for patients later this quarter. Late Thursday Synergy secured approval for a new constipation drug that will compete against a similar drug from Ironwood and ...

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that ...

The chronic idiopathic constipation (CIC) market has a new entrant. This was occasioned by the FDA’s approval of Trulance from Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The agency’s move triggers ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Synergy Pharmaceuticals announced it has ...

The FDA accepted Trulance Pharmaceutical’s supplemental new drug application for the treatment of irritable bowel syndrome with constipation. 1. The FDA previously approved Trulance for the treatment ...

FDA approves Trulance for chronic idiopathic constipation Trulance has been approved for the treatment of chronic idiopathic constipation in adults. The US Food and Drug Administration (FDA) has ...

Synergy Pharmaceuticals confirmed that FDA has approved Trulance™ (plecanatide), a once-daily, oral drug for treating chronic idiopathic constipation (CIC) in adults. The guanylate cyclase-C (GC-C) ...

Trulance (plecanatide; Synergy) has been approved by the Food and Drug Administration (FDA) for the treatment of chronic idiopathic constipation (CIC) in adult patients. Trulance (plecanatide tablets; ...